2.1 Study participants and sample collection
Participants were recruited as part of a pilot for the ACCENT
(A C anadian study of C isplatin
mE tabolomics and N ephroT oxicity) study, an
ongoing Canada-wide, multi-center initiative to identify serum and urine
metabolites for the prediction or early diagnosis of cisplatin-induced
nephrotoxicity. The ACCENT study is being conducted in accordance with
the Medical Association Declaration of Helsinki. After receiving written
informed consent, 31 adult patients were recruited at the London
Regional Cancer Program (Victoria Hospital, London, ON, Canada) between
2018-2020. Ethics approval for this study was obtained from the Health
Sciences Research Ethics Board at the University of Western Ontario. The
cohort included adult patients (>18 years of age)
initiating cisplatin treatment (dose ≥ 70 mg m2 -1)
for head and neck cancer. Exclusion criteria were chronic kidney disease
(GFR < 60 ml min-1) at baseline, previous
exposure to cisplatin/other nephrotoxic drugs in the 2 weeks leading up
to cisplatin treatment, radiotherapy within 1 month prior to the study,
or previous hematopoietic stem cell transplant. Patient demographic
information (Table 1 ) was recorded upon enrollment. Urine and
blood samples were collected from patients prior to (“pre”), 24–48
hours after (“24-48h”), and 5-14 days following (“post”) each
cisplatin infusion, and laboratory results/patient data were collected
for each sample collection timepoint. Samples were stored at -80°C prior
to analysis. A detailed outline of the ACCENT study has been previously
published.